136 reports of this reaction
1.5% of all IVACAFTOR reports
#14 most reported adverse reaction
PULMONARY FUNCTION TEST DECREASED is the #14 most commonly reported adverse reaction for IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 136 FDA adverse event reports linking IVACAFTOR to PULMONARY FUNCTION TEST DECREASED. This represents approximately 1.5% of all 9,200 adverse event reports for this drug.
Patients taking IVACAFTOR who experience pulmonary function test decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY FUNCTION TEST DECREASED is a less commonly reported adverse event for IVACAFTOR, but still significant enough to appear in the safety profile.
In addition to pulmonary function test decreased, the following adverse reactions have been reported for IVACAFTOR:
The following drugs have also been linked to pulmonary function test decreased in FDA adverse event reports:
PULMONARY FUNCTION TEST DECREASED has been reported as an adverse event in 136 FDA reports for IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY FUNCTION TEST DECREASED accounts for approximately 1.5% of all adverse event reports for IVACAFTOR, making it a notable side effect.
If you experience pulmonary function test decreased while taking IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.